Skip to content
DataLookout
Menu

NCT07909408

Psilocybin FCR Early-Stage Breast Cancer

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Fear of Cancer Recurrence Inventory-Short Form (FCRI-SF)
Timeframe: Baseline, Week 4 Post-Dose Session

Secondary (5)

Change in Clinical Global Impression-Severity (CGI-S) Score
Clinical Global Impression-Improvement (CGI-S) Score
Change in Hospital Anxiety and Depression Scale (HADS) Score
Change in Functional Assessment of Cancer Therapy-Breast (FACT-B) Score
Change in Functional Assessment of Chronic Illness Therapy-Spiritual well-being, 12-items (FACIT-Sp-12) Score

Arms and interventions

Psilocybin 25mgExperimental

1 medication session lasting approximately 8 hours

Psilocybin 5mgActive comparator

1 medication session lasting approximately 8 hours

Drugs: Psilocybin 25 mg, Psilocybin 5 mg

Sites

2 sites in 1 country